TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand
1 (PD-L1) pathway can induce robust and durable responses in patients with various …
1 (PD-L1) pathway can induce robust and durable responses in patients with various …
[HTML][HTML] Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
… Thomas Powles et al. report the results of a clinical phase I study in metastatic urothelial
bladder cancer treated with the anti-PDL1 antibody MPDL3280A. The transmembrane protein …
bladder cancer treated with the anti-PDL1 antibody MPDL3280A. The transmembrane protein …
[HTML][HTML] Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles… - … England Journal of …, 2015 - Mass Medical Soc
Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles… - The Lancet, 2017 - thelancet.com
Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival, …
metastatic urothelial carcinoma is associated with short response duration, poor survival, …
[HTML][HTML] Enfortumab vedotin in previously treated advanced urothelial carcinoma
T Powles, JE Rosenberg, GP Sonpavde… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with advanced urothelial carcinoma have poor overall survival after
platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or …
platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or …
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
T Powles, ZJ Assaf, N Davarpanah, R Banchereau… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic …
T Powles, MS van der Heijden, D Castellano… - The Lancet …, 2020 - thelancet.com
Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a …
JE Rosenberg, J Hoffman-Censits, T Powles… - The Lancet, 2016 - thelancet.com
Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…
[HTML][HTML] Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma
…, DI Quinn, T Powles - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …